Cargando…
免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习
A patient with advanced lung adenocarcinoma developed symptoms of frequent urination and urgent urination after 14 cycles of Pembrolizumab combined with chemotherapy. After making comprehensive analysis of the results of urine routine test, renal function, cystoscope and computed tomography (CT) exa...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial board of Chinese Journal of Lung Cancer
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600747/ https://www.ncbi.nlm.nih.gov/pubmed/37985157 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.106.17 |
_version_ | 1785126051912876032 |
---|---|
author | LI, Shishi ZHENG, Ke XU, Yan WANG, Mengzhao |
author_facet | LI, Shishi ZHENG, Ke XU, Yan WANG, Mengzhao |
author_sort | LI, Shishi |
collection | PubMed |
description | A patient with advanced lung adenocarcinoma developed symptoms of frequent urination and urgent urination after 14 cycles of Pembrolizumab combined with chemotherapy. After making comprehensive analysis of the results of urine routine test, renal function, cystoscope and computed tomography (CT) examination, immune checkpoint inhibitors related cystoureteritis and acute kidney injury were considered. The patient’s symptoms were relieved after discontinuation of Pembrolizumab combined with chemotherapy. However, the symptoms of urinary irritation worsened significantly after rechallenging Pembrolizumab combined with chemotherapy, and the symptoms was relieved after corticosteroids treatment. If patients develop urinary symptoms during immune checkpoint inhibitors treatment, immune checkpoint inhibitors related cystoureteritis should be considered for early differential diagnosis in order to implement appropriate treatment. |
format | Online Article Text |
id | pubmed-10600747 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Editorial board of Chinese Journal of Lung Cancer |
record_format | MEDLINE/PubMed |
spelling | pubmed-106007472023-10-27 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习 LI, Shishi ZHENG, Ke XU, Yan WANG, Mengzhao Zhongguo Fei Ai Za Zhi Case Report A patient with advanced lung adenocarcinoma developed symptoms of frequent urination and urgent urination after 14 cycles of Pembrolizumab combined with chemotherapy. After making comprehensive analysis of the results of urine routine test, renal function, cystoscope and computed tomography (CT) examination, immune checkpoint inhibitors related cystoureteritis and acute kidney injury were considered. The patient’s symptoms were relieved after discontinuation of Pembrolizumab combined with chemotherapy. However, the symptoms of urinary irritation worsened significantly after rechallenging Pembrolizumab combined with chemotherapy, and the symptoms was relieved after corticosteroids treatment. If patients develop urinary symptoms during immune checkpoint inhibitors treatment, immune checkpoint inhibitors related cystoureteritis should be considered for early differential diagnosis in order to implement appropriate treatment. Editorial board of Chinese Journal of Lung Cancer 2023-09-20 /pmc/articles/PMC10600747/ /pubmed/37985157 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.106.17 Text en 版权所有 © 2023《中国肺癌杂志》编辑部 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/. |
spellingShingle | Case Report LI, Shishi ZHENG, Ke XU, Yan WANG, Mengzhao 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习 |
title | 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习 |
title_full | 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习 |
title_fullStr | 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习 |
title_full_unstemmed | 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习 |
title_short | 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习 |
title_sort | 免疫检查点抑制剂相关输尿管膀胱炎:病例报道1例及文献复习 |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600747/ https://www.ncbi.nlm.nih.gov/pubmed/37985157 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.106.17 |
work_keys_str_mv | AT lishishi miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānshūniàoguǎnbǎngguāngyánbìnglìbàodào1lìjíwénxiànfùxí AT zhengke miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānshūniàoguǎnbǎngguāngyánbìnglìbàodào1lìjíwénxiànfùxí AT xuyan miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānshūniàoguǎnbǎngguāngyánbìnglìbàodào1lìjíwénxiànfùxí AT wangmengzhao miǎnyìjiǎnchádiǎnyìzhìjìxiāngguānshūniàoguǎnbǎngguāngyánbìnglìbàodào1lìjíwénxiànfùxí |